Phase I study of short-time oxaliplatin, capecitabine and epirubicin (EXE) as first line therapy in patients with non-resectable gastric cancer

References

• Coleman MP, Gatta G, Verdecchia A, et al. Eurocare-3 summary: Cancer survival in Europe at the end of the 20th century. Ann Oncol 2003; 14(Suppl 5)128–49
   PubMedGoogle Scholar
• Boyle P, Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann Oncol 2005; 16: 481–8
   PubMed Web of Science ®Google Scholar
• Janunger KG, Hafstrom L, Nygren P, et al. A systematic overview of chemotherapy effects in gastric cancer. Acta Oncol 2001; 40: 309–26
   PubMed Web of Science ®Google Scholar
• Hill ME, Cunningham D. Medical management of advanced gastric cancer. Cancer Treat Rev 1998; 24: 113–8
   PubMedGoogle Scholar
• Glimelius B, Ekström K, Hoffman K, et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 1997; 8: 163–8
   PubMed Web of Science ®Google Scholar
• Wils JA, Klein HO, Wagener DJ, et al. Sequential high-dose methotrexate and fluorouracil combined with doxorubicin–a step ahead in the treatment of advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J Clin Oncol 1991; 9: 827–31
   PubMed Web of Science ®Google Scholar
• Waters JS, Norman A, Cunningham D, et al. Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: Results of a randomized trial. Br J Cancer 1999; 80: 269–72
   PubMed Web of Science ®Google Scholar
• Webb A, Cunningham D, Scarffe JH, et al. Randomized trial comparing epirubicin, cisplatin and fluorouracil versus fluorouracil, doxorubicin and methotrexate in advanced esophagogastric cancer. J Clin Oncol 1997; 15: 261–7
   PubMed Web of Science ®Google Scholar
• Findlay, M, Cunningham, Norman, A, et al. A phase II study in advanced gastro-oesophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF). Ann Oncol 1994;5:609–16.
   PubMed Web of Science ®Google Scholar
• Evans TR, Lofts FJ, Mansi JL, Glees JP, Dalgleish AG, Knight MJ. A phase II study of continuous infusion 5-fluorouracil with cisplatin and epirubicin in inoperable pancreatic cancer. Br J Cancer 1996; 73: 1260–4
   PubMed Web of Science ®Google Scholar
• Miwa M, Ura M, Nishida M, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumors by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998; 34: 1274–81
   PubMed Web of Science ®Google Scholar
• Louvet C, Andre T, Tigaud JM, et al. Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients. J Clin Oncol 2002; 20: 4543–8
   PubMed Web of Science ®Google Scholar
• Al-Batran SE, Atmaca A, Hegewisch-Becker S, et al. Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer. J Clin Oncol 2004; 22: 658–63
   PubMed Web of Science ®Google Scholar
• Chao Y, Yeh KH, Chang CJ, et al. Phase II study of weekly oxaliplatin and 24-h infusion of high-dose 5-fluorouracil and folinic acid in the treatment of advanced gastric cancer. Br J Cancer 2004; 91: 453–8
   PubMed Web of Science ®Google Scholar
• Cvitkovic E, Bekradda M. Oxaliplatin: A new therapeutic option in colorectal cancer. Semin Oncol 1999; 26: 647–62
   PubMed Web of Science ®Google Scholar
• Pfeiffer P, Hahn P, Jensen HA. Short-time infusion of oxaliplatin (Eloxatin) in combination with capecitabine (Xeloda) in patients with advanced colorectal cancer. Acta Oncol 2003; 42: 832–6
   PubMed Web of Science ®Google Scholar
• Pfeiffer P, Sorbye H, Ehrsson H, et al. Short-time infusion of oxaliplatin in combination with capecitabine (Xelox30) as second line therapy in patients with advanced colorectal cancer after failure to irinotecan and 5-fluorouracil. Ann Oncol 2006; 33: 70–4
   Google Scholar
• Sumpter K, Harper-Wynne C, Cunningham D, et al. Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF. Br J Cancer 2005; 92: 1976–83
   PubMed Web of Science ®Google Scholar
• Hong YS, Song SY, Lee SI, et al. A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer. Ann Oncol 2004; 15: 1344–7
   PubMed Web of Science ®Google Scholar
• Tsai JY, Iannitti D, Berkenblit A, et al. Phase 1 study of docetaxel, capecitabine, and carboplatin in metastatic esophagogastric cancer. Am J Clin Oncol 2005; 28: 329–33
   PubMed Web of Science ®Google Scholar
• Ychou M, Conroy T, Seitz JF, et al. An open phase 1 study assessing the feasibility of the triple combination: Oxaliplatin plus irinotecan plus leucovorin/5-fluorouracil every 2 weeks in patients with advanced solid tumors. Ann Oncol 2003; 14: 481–9
   PubMed Web of Science ®Google Scholar
• Idelevich, E, Karminsky, N, Dinerman, M, et al. Phase II study of cisplatin, epirubicin, UFT, and leucovorin (PELUF) as first-line therapy in metastatic gastric cancer. Acta Oncol, (in press).
   Google Scholar